TY - JOUR
T1 - Weight loss associated with HIV seroconversion among injection-drug users
AU - Marmor, Michael
AU - Titus, Stephen
AU - Harrison, Cynthia
AU - Cord-Cruz, Evyan Argonza
AU - Shore, Roy E.
AU - Vogler, Mary
AU - Krasinski, Keith
AU - Mildvan, Donna
AU - Des Jarlais, Don C.
PY - 1996
Y1 - 1996
N2 - To describe symptoms associated with human immunodeficiency virus (HIV) seroconversion, we studied a cohort of 366 injection-drug users (IDUs) with a study design that included recall every 3 months to collect symptom histories using a structured questionnaire. Eleven HIV seroconversions were observed in 621.5 person years at risk (PYAR), equivalent to 1.8 seroconversions/100 PYAR. Cox regression analysis showed age ≤35 years to be a significant risk factor for HIV seroconversion after controlling for gender, race, and the frequency of drug injection. An embedded case-control analysis then compared symptom histories of HIV seroconverters with those of age-(±5 years) and visit number-matched controls who remained HIV seronegative for ≤3 months longer than the HIV-seroconverters. Multivariate case-control analysis adjusted for injection frequency yielded significant associations of HIV seroconversion with histories of weight loss ≤4.5 kg (seven of 11 cases; odds ratio [OR] 11.6, 95% confidence interval [CI] 3.1, 43.1) and oral ulcers (three of 11 cases; OR = 7.6, 95% CI = 1.2, 48.2) in the 3 months before the subjects' first HIV-seropositive study visit. We conclude that histories of recent symptoms reported by HIV-seroconverting IDUs differ from those reported by non-HIV-seroconverting IDUs, and weight loss may be particularly common among IDUs experiencing primary HIV infection.
AB - To describe symptoms associated with human immunodeficiency virus (HIV) seroconversion, we studied a cohort of 366 injection-drug users (IDUs) with a study design that included recall every 3 months to collect symptom histories using a structured questionnaire. Eleven HIV seroconversions were observed in 621.5 person years at risk (PYAR), equivalent to 1.8 seroconversions/100 PYAR. Cox regression analysis showed age ≤35 years to be a significant risk factor for HIV seroconversion after controlling for gender, race, and the frequency of drug injection. An embedded case-control analysis then compared symptom histories of HIV seroconverters with those of age-(±5 years) and visit number-matched controls who remained HIV seronegative for ≤3 months longer than the HIV-seroconverters. Multivariate case-control analysis adjusted for injection frequency yielded significant associations of HIV seroconversion with histories of weight loss ≤4.5 kg (seven of 11 cases; odds ratio [OR] 11.6, 95% confidence interval [CI] 3.1, 43.1) and oral ulcers (three of 11 cases; OR = 7.6, 95% CI = 1.2, 48.2) in the 3 months before the subjects' first HIV-seropositive study visit. We conclude that histories of recent symptoms reported by HIV-seroconverting IDUs differ from those reported by non-HIV-seroconverting IDUs, and weight loss may be particularly common among IDUs experiencing primary HIV infection.
KW - Acute retroviral syndrome
KW - Epidemiology
KW - Human immunodeficiency syndrome
KW - Injection drug use
UR - http://www.scopus.com/inward/record.url?scp=0029818440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029818440&partnerID=8YFLogxK
U2 - 10.1097/00042560-199608150-00012
DO - 10.1097/00042560-199608150-00012
M3 - Article
C2 - 8757430
AN - SCOPUS:0029818440
SN - 1077-9450
VL - 12
SP - 514
EP - 518
JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
IS - 5
ER -